Stem Cells

<p>ROCK inhibitor-2 is a selective dual inhibitor of ROCK1 and ROCK2 (IC50s of 17 nM and 2 nM, respectively).</p>

<p>Nefopam hydrochloride (Nefopam HCl) is the hydrochloride salt form of nefopam, a centrally-acting, non-opioid benzoxazocine with analgesic activity.</p>

<p>TNIK-IN-5: strong TNIK inhibitor (IC50=0.05μM), halts Wnt signaling, effective against colorectal cancer in vitro.</p>

<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>

<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: &gt;14.7, &gt;30 μM).</p>

<p>KY1220 destabilizes both β-catenin and Ras by targeting the Wnt/β-catenin pathway. It has an IC50 of 2.1 μM in HEK293 reporter cells.</p>

<p>E2012 is a γ-secretase modulator (GSM).</p>

<p>Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.</p>

<p>CWP232228 is a selective Wnt/β-catenin pathway inhibitor targeting β-catenin/TCF binding, halting breast/liver CSC growth and metastasis safely.</p>

<p>Netarsudil Dihydrochloride (AR-13324 Dihydrochloride) is an inhibitor of Rho-related protein kinase (ROCK) and norepinephrine transporter (NET) and is effective in reducing intraocular pressure (IOP).Cost-effective and quality-assured.</p>

<p>Garetosmab (REGN 2477), a human IgG4 monoclonal antibody, inhibits activin A for potential cancer treatment and FOP study.</p>

<p>NMS-P715 is a highly selective and ATP-competitive MPS1 inhibitor(IC50 of 182 nM).</p>

<p>Sonidegib diphosphate (LDE225 diphosphate) is a selective antagonist of Smo that inhibits murine Smo and human Smo.Cost-effective and quality-assured.</p>

<p>Ponsegromab (PF 06946860), a humanized anti-GDF15 antibody, may treat cancer cachexia by blocking GDF15/GFRAL signaling.</p>

<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>

<p>NGP555 is a modulator of γ-secretase.</p>

<p>BML-286 is a WNT pathway modulator with potential anticancer activity and induces β-catenin- and TCF- dependent transcriptional activity.</p>

<p>MRT-83 is a potent Smo antagonist.</p>

<p>CCT251545 is an potent and oral-bioavailable WNT signaling inhibitor(IC50 of 5 nM in 7dF3 cells).</p>

<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>

<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>

<p>JW74 antagonizes LiCl-induced activation of the canonical Wnt signaling (IC50: 420 nM).</p>

<p>Cyanoacetohydrazide (Cyanoacetic hydrazide) is an anti-TB drug. It has also been used to derive compounds that may have antitumor properties.</p>

<p>Silmitasertib sodium salt (CX-4945 sodium salt) is a potent and orally bioavailable, highly selective inhibitor of CK2(IC50 of 1 nM, CK2α).</p>

<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>

<p>BRD0705: potent, selective GSK3α inhibitor, oral, IC50: 66 nM, 8x more selective than GSK3β.</p>

<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>

<p>IK-930 is an orally active TEAD inhibitor (EC50 &lt; 0.1 µM) with potent potency.</p>

<p>1(R),2(S)-epoxy Cannabidiol (Compound 2a) is a structural analog of phytocannabinoids, exhibiting significant inhibitory activity on the Wnt/β-catenin pathway. It holds potential for research as a neuroprotective agent.</p>

<p>CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.</p>

<p>Wnt/β-catenin agonist 3 is a Wnt/beta-catenin agonist.</p>

<p>ROCK2-IN-9 (compound 7u), a selective ROCK2 inhibitor with an IC50 value of 36.8 nM, demonstrates anticancer properties by impeding cancer cell migration and invasion. This action is achieved through the regulation of various actin cytoskeleton cellular activities. It holds potential for use in breast cancer research.</p>

<p>STAT3-IN-31 (compound K2071), derived from STATtic, acts as an inhibitor of both STAT3 and mitotic processes. This compound interrupts mitotic progression and impacts the formation of the mitotic spindle. Additionally, STAT3-IN-31 hampers migration in glioblastoma cells, suppresses cellular proliferation within tumor spheroids, induces senescence in glioblastoma, and inhibits the growth of Temozolomide-resistant cells while reducing the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein (MCP-1).</p>

<p>Cirevetmab (ZTS-00521426), a caninized monoclonal antibody targeting Canis lupus familiaris TGFB1, is classified as an immunoglobulin G2-kappa.</p>

<p>TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, showing inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% for TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at 10 μM. It exhibits strong antiproliferative and antimigratory effects on prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds potential for research in the field of cancer therapeutics.</p>

<p>WAY-297174 is a human protein kinase CK2 inhibitor with IC50 of &gt; 33 μM.</p>

<p>RBPJ Inhibitor-1 (RIN1), a compound that impedes the functional interaction between RBPJ and SHARP, effectively inhibits NOTCH-dependent tumor cell</p>

<p>YAP-TEAD-IN-1 acetate is an effective and competitive inhibitor of YAP–TEAD interaction with an IC50 of 25 nM.</p>

<p>P17 Peptide, a human TGF-β1 inhibitory peptide, effectively blocks the activity of woodchuck TGF-β1.</p>

<p>Ripasudil free base (K-115 (free base)) is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent.</p>

<p>TGFβRI-IN-7 (compound 16W) is a potent inhibitor of TGFβRI. It effectively inhibits the phosphorylation of SMAD2/3 and reduces the viability of H22 cells, with IC50 values of 12 nM and 65 nM, respectively. In an H22 cell xenograft model, TGFβRI-IN-7 exhibits antitumor efficacy with a TGI of 79.6%.</p>

<p>Lerdelimumab (CAT-152) is an IgG4 monoclonal antibody targeting TGF-β2, used in glaucoma scarring research.</p>

<p>GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.</p>

<p>CK1δ-IN-6: potent, selective CK-1δ inhibitor, IC50 23 nM, neuroprotective, anti-inflammatory, for neurodegenerative research.</p>

<p>ABC99 irreversibly inhibits wnt-deacylating enzyme NOTUM (IC50: 13 nM) with high serine hydrolase family selectivity.</p>

<p>Wnt pathway inhibitor 3 is a potent AC1 inhibitor with an IC50 value of 45 nM.Wnt pathway inhibitor 3 has antiproliferative activity and can be used in studies</p>

<p>WAY-656935 inhibits ROCK.</p>

<p>Foxy-5 Ammonium Salt, a WNT5A mimetic, blocks epithelial cancer cell migration without β-catenin impact and curbs prostate cancer spread.</p>

<p>A unique collection of 237 Wnt/Hedgehog/Notch signaling targeted compounds for high throughput and high content screening;</p>

<p>Sotatercept (ACE-011) is an ActRIIA-Fc fusion protein and an inhibitor of activin signaling.</p>